While potentially decreasing the effective dose, this strategy does not address, and may compound, the issue of IFNα toxicity due to the extended half-life generally observed with antibody based therapies and the ubiquitous expression of the interferon-α receptor (IFNAR) on non-tumor cells. The gene discussed is IFNA2; the disease is neoplasm.